What question did this study set out to answer?

This research aims to explore metabolic alterations in astrocytes treated with Aβ1-42, comparing responses between Alzheimer's Disease patients and healthy subjects.

March 8, 2026MetabolitesOpen Access

An NMR-Based Protocol for Profiling the Endo- and Exo-Metabolomes in Aβ1-42 Treated Human Astrocytes from Healthy and Alzheimer’s Disease Donors

View Full Paper

Ask AI

Bookmark

Authors

EBElisa Bientinesi AVAlessia Vignoli SRSara Ristori

Discussion

Member takes

Overview

Metabolomic profiling reveals altered responses in astrocytes from Alzheimer's Disease patients, suggesting distinct metabolic adaptations to Aβ-induced stress.

Key Points

This research aims to explore metabolic alterations in astrocytes treated with Aβ1-42, comparing responses between Alzheimer's Disease patients and healthy subjects.
Optimized protocol for untargeted metabolomic profiling using NMR spectroscopy.
Primary human astrocytes were derived from Alzheimer's Disease patients and healthy subjects.
Cells were treated with oligomeric Aβ1-42 to simulate pathological conditions.
Aβ1-42 treatment induced reductions in phosphocreatine and β-alanine in astrocytes.
Differential extracellular metabolic responses were observed: AD astrocytes showed increased levels of 2-oxoglutarate, citrate, and glycine.
Healthy subjects showed reduced levels of leucine and isoleucine, indicating distinct adaptive responses.

Cite This Study

Bientinesi et al. (2026) studied this question.

synapsesocial.com/papers/69acc58f32b0ef16a404fe4f https://doi.org/10.3390/metabo16030173

View Full Paper

Ask AI

Bookmark

March 8, 2026MetabolitesOpen Access

An NMR-Based Protocol for Profiling the Endo- and Exo-Metabolomes in Aβ1-42 Treated Human Astrocytes from Healthy and Alzheimer’s Disease Donors

View Full Paper

Ask AI

Bookmark

Authors

EBElisa Bientinesi AVAlessia Vignoli SRSara Ristori

Discussion

Member takes

Overview

Metabolomic profiling reveals altered responses in astrocytes from Alzheimer's Disease patients, suggesting distinct metabolic adaptations to Aβ-induced stress.

Key Points

This research aims to explore metabolic alterations in astrocytes treated with Aβ1-42, comparing responses between Alzheimer's Disease patients and healthy subjects.
Optimized protocol for untargeted metabolomic profiling using NMR spectroscopy.
Primary human astrocytes were derived from Alzheimer's Disease patients and healthy subjects.
Cells were treated with oligomeric Aβ1-42 to simulate pathological conditions.
Aβ1-42 treatment induced reductions in phosphocreatine and β-alanine in astrocytes.
Differential extracellular metabolic responses were observed: AD astrocytes showed increased levels of 2-oxoglutarate, citrate, and glycine.
Healthy subjects showed reduced levels of leucine and isoleucine, indicating distinct adaptive responses.

Cite This Study

Bientinesi et al. (2026) studied this question.

synapsesocial.com/papers/69acc58f32b0ef16a404fe4f https://doi.org/10.3390/metabo16030173

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark